• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study

tetano

Editor, Senior Moderator
J Antimicrob Chemother. 2011 Mar 9. [Epub ahead of print]
Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.

Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M.

School of Public Health, Tel-Aviv University, Ramat Aviv, Israel.
Abstract

Background We assessed the association between early oseltamivir treatment and influenza complications in hospitalized patients. Methods A retrospective cohort study, including adults with laboratory-confirmed 2009 influenza A (H1N1) in three hospitals in Israel, was performed between July 2009 and January 2010, when admission was limited to high-risk patients. We compared patients treated with oseltamivir early versus late (>48 h after symptom onset). We analysed risk factors for complications, defined as radiographic pneumonia, hypoxia, mechanical ventilation, intensive care unit admission, haemodynamic support or in-hospital death. Risk factors for complications on univariate analysis were entered into a multivariable logistic regression analysis. Odds ratios (ORs) with 95% confidence intervals (CI) are reported. Results Four hundred and forty-nine inpatients treated with oseltamivir were included, 189 (42.1%) of whom were treated early. Influenza complications occurred significantly more frequently among patients treated late with oseltamivir [150/260 (57.7%) versus 67/189 (35.4%), P < 0.001]. Late oseltamivir remained significantly associated with complications in the adjusted analysis (OR 2.37, 95% CI 1.52-3.70). Other independent risk factors included dyspnoea, disease severity on admission, lower sodium and treatment at one hospital; rhinorrhoea was protective. In an analysis adjusted for the propensity for early treatment the association remained significant (OR 2.21, 95% CI 1.41-3.46). Initiation of oseltamivir >48 h after admission was associated with a higher rate of complications documented after admission (OR 4.09, 95% CI 1.55-10.80). Severe complications (excluding hypoxia and uncomplicated pneumonia) occurred more frequently with late oseltamivir (adjusted OR 3.28,95% CI 1.56-6.89). Conclusions Initiation of oseltamivir within 48 h of symptom onset was associated with fewer complications in patients hospitalized with 2009 influenza A (H1N1).

PMID: 21393197 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/21393197
 
Back
Top Bottom